Results showed in Figure 5(a), compared to aGVHD mice receiving untreated donor cells, GVHD+Fluvastatin mice possessed a higher percentage of CD62L+ CD3+ T cells in the early stage in blood and in SLOs (day 3 and day 7). The gene discussed is SELL; the disease is graft versus host disease.